NCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
Clinical Trials
272 trialsNCT04633122 2026-04-03
A Study to Assess DCC-2618 and Sunitinib in Patients With Advanced GIST After Treatment With Imatinib
Zai Lab (Hong Kong), Ltd.
Phase 2 Completed
NCT02555748 2026-03-31
SUP-R
Institut Claudius Regaud
Phase 4 Completed
NCT05381753 2026-02-11
Safety and Efficacy of Avapritinib in Chinese Patients With Gastrointestinal Stromal Tumor (GIST) in the Real World
CStone Pharmaceuticals
Completed
NCT01391962 2026-02-02
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT02853331 2026-02-02
KEYNOTE-426
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT04394975 2025-11-28
Study to Evaluate the Efficacy and Safety of Toripalimab in Combination With Axitinib Versus Sunitinib Monotherapy in Advanced Renal Cell Cancer
Shanghai Junshi Bioscience Co., Ltd.
Phase 3 Completed
NCT00930033 2025-09-05
CARMENA
Assistance Publique - Hôpitaux de Paris
Phase 3 Completed
NCT02684006 2025-07-30
JAVELIN Renal 101
Pfizer
Phase 3 Completed
NCT03260894 2025-07-29
Pembrolizumab (MK-3475) Plus Epacadostat vs Standard of Care in mRCC (KEYNOTE-679/ECHO-302)
Incyte Corporation
Phase 3 Completed
NCT01286896 2025-07-10
Use of Individual Pharmacokinetically (PK)-Guided Sunitinib Dosing: A Feasibility Study in Patients With Advanced Solid Tumors
The Netherlands Cancer Institute
Phase 1 Completed
NCT02231749 2025-06-26
Nivolumab Combined With Ipilimumab Versus Sunitinib in Previously Untreated Advanced or Metastatic Renal Cell Carcinoma (CheckMate 214)
Bristol-Myers Squibb
Phase 3 Completed
NCT00437372 2025-05-02
Phase IB Study Using Sunitinib Plus Radiation Therapy for Cancer Patients
Thomas Jefferson University
Phase 1 Completed
NCT02230176 2025-04-20
OCCLURANDOM
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT00720941 2025-03-30
COMPARZ
Novartis
Phase 3 Completed
NCT00381641 2025-03-28
Sunitinib Malate in Treating Patients With Thyroid Cancer That Did Not Respond to Iodine I 131 and Cannot Be Removed by Surgery
National Cancer Institute (NCI)
Phase 2 Completed
NCT01147822 2025-03-28
Pazopanib Versus Sunitinib in the Treatment of Asian Subjects With Locally Advanced and/or Metastatic Renal Cell Carcinoma
Novartis
Phase 2 Completed
NCT02401815 2025-02-14
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
Cogent Biosciences, Inc.
Phase 1/2 Completed
NCT01254864 2025-01-27
Maximal Androgen Depletion Followed by Randomization of Maximal Androgen Ablation With Molecular Targeted Therapies
M.D. Anderson Cancer Center
Phase 2 Completed
NCT02761057 2025-01-13
Testing Cabozantinib, Crizotinib, Savolitinib and Sunitinib in Kidney Cancer Which Has Progressed
National Cancer Institute (NCI)
Phase 2 Completed
NCT00843037 2024-10-17
SNIPP
University Health Network, Toronto
Phase 2 Completed
NCT03109015 2024-10-08
ASSET
Duke University
Phase 2 Completed
NCT01306045 2024-10-01
Molecular Profiling and Targeted Therapy for Advanced Non-Small Cell Lung Cancer, Small Cell Lung Cancer, and Thymic Malignancies
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01621568 2024-09-24
Sunitinib for Advanced Thymus Cancer Following Earlier Treatment
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00700258 2024-09-23
STAR-TOR
Pfizer
Completed
NCT03277924 2024-08-13
ImmunoSarc
Grupo Espanol de Investigacion en Sarcomas
Phase 1/2 Completed
NCT05745142 2024-08-05
A Study to go Back Into Records and Observe How People With Metastatic Renal Cell Carcinoma (mRCC) Who Received a Medicine Called Sunitinib Responded to This Medicine.
Pfizer
Completed
NCT04669366 2024-07-19
Treatment Patterns With Targeted Therapies In Mrcc In Sweden - A Retrospective Analysis Of Data From National Registries
Pfizer
Completed
NCT02282059 2024-06-20
The Safety And Efficacy Of Sunitinib In Chinese Patients With Progressive Advanced Or Metastatic Well-Differentiated Unresectable Pancreatic Neuroendocrine Tumors
Pfizer
Completed
NCT00482755 2024-02-12
Sunitinib in Treating Patients With Newly Diagnosed Stage II or Stage III Breast Cancer That Can Be Removed by Surgery
Canadian Cancer Trials Group
Phase 2 Completed
NCT02483247 2023-11-14
A Study of BBI503 in Combination With Selected Anti-Cancer Therapeutics in Adult Patients With Advanced Cancer
Sumitomo Pharma America, Inc.
Phase 1 Completed
NCT02264665 2023-11-13
OPALINE
Pfizer
Completed
NCT01517243 2023-09-21
Phase II Study of Alternating Sunitinib and Temsirolimus
Dartmouth-Hitchcock Medical Center
Phase 2 Completed
NCT00813423 2023-08-02
Sunitinib Malate and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors That Have Not Responded to Chemotherapy
National Cancer Institute (NCI)
Phase 1 Completed
NCT01164228 2023-06-15
Sunitinib Malate With or Without Gemcitabine Hydrochloride in Treating Patients With Advanced Kidney Cancer That Cannot Be Removed By Surgery
Eastern Cooperative Oncology Group
Phase 2 Completed
NCT00656669 2023-05-23
Exploratory Study of Sunitinib Malate as a Component of Neoadjuvant Therapy for Breast Cancer
Indiana University
Phase NA Completed
NCT00716625 2023-05-03
Special Investigation For Renal Cell Carcinoma (RCC) Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan)
Pfizer
Completed
NCT04175262 2023-05-03
Clinical Outcomes For Patients With Metastatic Renal Cell Carcinoma (mRCC) Who Received Sunitinib After 1st Line Immune-oncology (IO) Treatments
Pfizer
Completed
NCT05800106 2023-04-10
A Bioequivalence Study of Sunitinib Malate Capsules.
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1 Completed
NCT00716820 2023-04-06
Special Investigation For Gist Of Sunitinib Malate (Regulatory Post Marketing Commitment Plan).
Pfizer
Completed
NCT04033991 2023-04-06
Study of Patients With Metastatic and/or Advanced Renal Cell Carcinoma, Treated With Sunitinib/Axitinib.
Pfizer
Completed
NCT04076787 2023-04-06
Clinical Outcomes for Patients With Renal Cell Carcinoma Who Received First-Line Sunitinib
Pfizer
Completed
NCT00453154 2023-04-04
Cisplatin or Carboplatin, and Etoposide With or Without Sunitinib Malate in Treating Patients With Extensive-Stage Small Cell Lung Cancer
National Cancer Institute (NCI)
Phase 1/2 Completed
NCT02420821 2023-01-30
IMmotion151
Hoffmann-La Roche
Phase 3 Completed
NCT00270413 2022-11-22
SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT00981890 2022-10-07
Stereotactic Radiosurgery With Sunitinib for Brain Metastases
University Health Network, Toronto
Phase 1 Completed
NCT02432846 2022-08-22
MERECA
Mendus
Phase 2 Completed
NCT01061411 2022-08-05
Dalteparin and Sunitinib Malate as First-Line Therapy in Treating Patients With Kidney Cancer That is Metastatic or Cannot Be Removed by Surgery
Roswell Park Cancer Institute
Phase 1 Completed
NCT01371201 2022-08-04
FIRSTMAPPP
Gustave Roussy, Cancer Campus, Grand Paris
Phase 2 Completed
NCT02450123 2022-06-15
Single-arm Study to Evaluate the Safety and Efficacy of Sunitinib, in Subjects With RET Fusion Positive or FGFR2 Amplification, Refractory Solid Tumors
Samsung Medical Center
Phase NA Completed